Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Mar 1;6(3):e236324.
doi: 10.1001/jamanetworkopen.2023.6324.

Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis

Tomáš Blažek  1   2   3 , Marek Petráš  3 , Lukáš Knybel  1   2 , Jakub Cvek  1   2 , Renata Soumarová  4
Affiliations
Meta-Analysis

Programmed Cell Death Ligand 1 Expression on Immune Cells and Survival in Patients With Nonmetastatic Head and Neck Cancer: A Systematic Review and Meta-analysis

Tomáš Blažek et al. JAMA Netw Open. .

Abstract

Importance: The failure or success of radical treatment in patients with head and neck squamous cell carcinoma (HNSCC) is associated with many known and unknown factors; hence, there is a search for further prognostic markers to help optimize therapeutic strategy and improve treatment outcomes.

Objective: To assess the association of programmed cell death ligand 1 (PD-L1) expression on immune or tumor cells, including its composite expression on both cell types, with overall survival (OS) or specific survival.

Data sources: MEDLINE, Embase, PQSciTech, and HCAPlus databases were systematically searched for cohort studies focused on the prognostic role of PD-L1 expression in patients with HNSCC in curative stages of the disease. Search results generated publications from January 1, 2010, to January 6, 2023.

Study selection: Of 3825 publications identified, a total of 17 cohort studies in the English language met inclusion criteria of this systematic review and meta-analysis. Eligible studies reported adjusted hazard ratios (aHRs) with 95% CIs for the association of PD-L1 expression levels with OS and arbitrary specific survival.

Data extraction and synthesis: Data from studies were extracted independently by 2 researchers strictly adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines and recommendations. The risk of bias was assessed using the Quality in Prognosis Studies tool and Newcastle-Ottawa Scale. Pooled effect estimates were obtained using a random-effect or fixed-effect model based on homogeneity of studies.

Main outcomes and measures: The primary outcome was to investigate whether there was an association between PD-L1 expression on immune or tumor cells and OS.

Results: In 17 cohort studies of the association of PD-L1 expression with survival in 3190 patients with HNSCC, high PD-L1 expression on immune cells was associated with a favorable OS (pooled aHR, 0.39; 95% CI, 0.25-0.59). There was no association between composite PD-L1 expression on immune and tumor cells and OS (pooled aHR, 0.79; 95% CI, 0.55-1.14) or between PD-L1 expressed only on tumor cells and OS (pooled aHR, 1.22; 95% CI, 0.87-1.70). A high level of PD-L1 expression on immune cells was associated with favorable specific survival (pooled aHR, 0.52; 95% CI, 0.38-0.72). There were no interactions between tumor location or type of primary treatment (ie, surgery vs radiotherapy or radiochemotherapy) and the association between PD-L1 expression and OS.

Conclusions and relevance: This study's findings suggest that PD-L1 expression on immune cells may serve as a new prognostic biomarker in patients with HNSCC. However, future studies may be warranted to verify this potential role given the limited number of studies on this topic conducted and published to date.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Knybel reported receiving grants from University Hospital Ostrava by the Ministry of Health of the Czech Republic and European Union Horizon 2020 research and innovation program outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Flowchart
Figure 2.
Figure 2.. Association of Programmed Cell Death Ligand 1 Expression Levels With Overall Survival
Results are presented from a random-effects model, including τ2 (heterogeneity variance), I2 (inconsistency index), H2 (H statistics), and P value. aHR indicates adjusted hazard ratio; box size, weight of the aHR (effect size); dashed lines, overall pooled aHRs; diamonds, pooled aHRs; IC, immune cell; lateral points, 95% CIs; NA, not applicable; TC, tumor cell.
See this image and copyright information in PMC

References

    1. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591-5596. doi:10.1242/jcs.116392 - DOI - PubMed
    1. Curry JM, Sprandio J, Cognetti D, et al. . Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol. 2014;41(2):217-234. doi:10.1053/j.seminoncol.2014.03.003 - DOI - PubMed
    1. Binnewies M, Roberts EW, Kersten K, et al. . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi:10.1038/s41591-018-0014-x - DOI - PMC - PubMed
    1. Hadrup S, Donia M, Thor Straten P. Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron. 2013;6(2):123-133. doi:10.1007/s12307-012-0127-6 - DOI - PMC - PubMed
    1. Angell H, Galon J. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261-267. doi:10.1016/j.coi.2013.03.004 - DOI - PubMed

Publication types